IV infusionAcute infections Adult & childn >12 yr 10 mL every 12 hr. Childn ≤12 yr 6 mg trimethoprim & 30 mg sulfamethoxazole/kg/24 hr in 2 equally divided doses, 6-12 yr 5 mL every 12 hr, 6 mth-5 yr 2.5 mL every 12 hr, 6 wk-5 mth 1.25 mL every 12 hr. Severe infections May be increased by 50%. Treatment should be continued until patient is symptom free for 2 days. Renal impairment CrCl >30 mL/min Standard dosage, 15-30 mL/min ½ the standard dosage.
View Trimozol overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to sulfamethoxazole, trimethoprim or sulphonamides. Marked liver parenchymal damage, severe renal insufficiency. Premature babies, full-term infants during the 1st 6 wk of life except for the treatment/prophylaxis of PCP in infants 4 wk of age or greater.
Stevens-Johnson syndrome & toxic epidermal necrolysis. Closely monitor for skin reactions. Fluid overload especially in very high doses administered to patients w/ underlying cardiopulmonary disease. Maintain adequate urinary output at all times. Patients suffering from malnutrition, G6PD patients, patients w/ severe allergy or bronchial asthma. Not for the treatment of streptococcal pharyngitis due to group A β-hemolytic streptococci. Avoid in patients known or suspected to be at risk of acute porphyria. Concomitant use w/ sulphonylurea & hypoglycaemic agents. Regular mthly blood counts are advisable in long periods or to folate deficient patients or elderly. Renal & kidney impairment. Elderly.
Difficulty in breathing, fainting, swelling of face, mouth, tongue or throat, chest pain, red patches on the skin; high levels of K in the blood; thrush or candidiasis, headache, nausea, diarrhea, skin rashes.
Drug Interactions
May interfere w/ the estimation of serum/plasma creatinine w/ alkaline picrate. May increase risk of hematological adverse reactions w/ zidovudine. Reversible deterioration in renal function w/ ciclosporin. May increase plasma conc w/ procainamide & amantadine. Increased risk of thrombocytopenia in elderly concurrently receiving diuretics mainly thiazides. May develop megaloblastic anemia w/ pyrimethamine. Potentiates anticoagulant activity of warfarin. Prolonged t½ of phenytoin. Increased plasma levels of digoxin & methotrexate. Increase lamivudine exposure. Medications that can cause hyperkalemia.
J01EE01 - sulfamethoxazole and trimethoprim ; Belongs to the class of combinations of sulfonamides and trimethoprim, including derivatives. Used in the systemic treatment of infections.
Sign Out
